Table 2.

General overview of some key trials that have explored the impact of neoadjuvant chemotherapy (NACT) on overall survival in early-stage triple-negative breast cancer (TNBC)

	Intervention	Outcome
GeparSixto (2013) [1]	Anthracycline/taxane + carboplatin vs. anthracycline/taxane	Although the primary endpoint was pathological complete response (pCR), this trial did not directly assess overall survival. It demonstrated an increase in pCR with the addition of carboplatin, which can be associated with improved long-term outcomes
CREATE-X (2017)	Capecitabine vs. Observation following standard adjuvant chemotherapy	While CREATE-X focused on the adjuvant setting, it is noteworthy for its impact on overall survival. Patients receiving capecitabine post-surgery showed a significant improvement in disease-free survival, and a trend towards improved overall survival was observed
KEYNOTE-522 (2019)	Pembrolizumab + chemotherapy vs. placebo + chemotherapy	While the primary endpoint was pCR, the trial demonstrated a potential trend toward improved event-free survival. The overall survival data may become more mature over time
IMpassion031 (2020)	Atezolizumab + chemotherapy vs. placebo + chemotherapy	The trial showed an improvement in invasive disease-free survival in the intention-to-treat population, which could suggest a potential benefit in overall survival. However, mature overall survival data may require further follow-up